Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2026 Earnings Call Transcript May 7, 2026Xenon Pharmaceuticals Inc. reports earnings inline with expectations.
Xenon Pharmaceuticals Inc. (XENE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Atika Capital Brad Farber | 59,900 | $3,483,185 | -36% | 0.44% |
| 2. | Rhenman & Partners Asset Management Henrik Rhenman | 28,000 | $1,628,200 | -80% | 0.2% |
| 3. | Hudson Bay Capital Management Sander Gerber | 14,072 | $818,287 | 0% | |
| 4. | Bayforest Capital Theodoros Tsagaris | 555 | $32,273 | 0.04% | |
| 5. | Dorset Management David M. Knott | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.81 | 700 | $20,167.00 | 700 | 2022-01-21 | Filing | |
| $24.40 | 4,000 | $97,600.00 | 4,000 | 2021-12-06 | Filing | |
| $2.22 | 15,000 | $33,280.50 | 44,210 | 2017-11-15 | Filing | |
| $2.95 | 8,000 | $23,600.00 | 29,210 | 2017-09-22 | Filing | |
| $2.95 | 2,000 | $5,900.00 | 21,210 | 2017-09-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $55.23 | 1,410 | $77,867.25 | 7,069 | 2026-03-13 | Filing | |
| $55.23 | 1,342 | $74,111.95 | 7,301 | 2026-03-13 | Filing | |
| $55.23 | 7,308 | $403,584.30 | 19,923 | 2026-03-13 | Filing | |
| $60.11 | 2,771 | $166,559.27 | 4,729 | 2026-03-10 | Filing | |
| $60.11 | 2,607 | $156,701.56 | 4,893 | 2026-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,640,118 | $327,972,862 | 0.01% | |
| 2. | 2,674,727 | $155,535,375 | 0.04% | |
| 3. | 1,923,610 | $106,856,563 | 0.01% | |
| 4. | 1,401,483 | $81,496,236 | 0.34% | |
| 5. | 1,318,814 | $76,689,035 | 0.05% |
News See All
10 Best 52-Week High US Stocks to Buy
“Investors appear to be treating an end to the US-Israeli war with Iran as a foregone conclusion, as the S&P 500 closes above 7,000.” This is the deck on the New York Times’ report on the S&P 500...
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward
Xenon Pharmaceuticals climbed by 31.7 percent week-on-week, as investor sentiment was bolstered by positive clinical trial for its epilepsy and depression treatment candidate, alongside plans to submit...
10 Stocks Making Huge Moves this Week: Fastly, Sasol, Hims and More
Month-to-date, Fastly Inc.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. My name is RJ, and I will be your conference operator today.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript August 11, 2025Xenon Pharmaceuticals Inc. misses on earnings expectations.
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Hedge Fund Resource Center